Show simple item record

dc.contributor.authorFelmingham, Kim L.
dc.contributor.authorDobson-Stone, Carol
dc.contributor.authorSchofield, Peter R.
dc.contributor.authorQuirk, Gregory J.
dc.contributor.authorBryant, Richard A.
dc.date.accessioned2017-05-26T19:51:14Z
dc.date.available2017-05-26T19:51:14Z
dc.date.issued2013
dc.identifier.citationFelmingham, K. L., Dobson-Stone, C., Schofield, P. R., Quirk, G. J., & Bryant, R. A. (2013). The Brain-Derived Neurotrophic Factor Val66Met Polymorphism Predicts Response to Exposure Therapy in Posttraumatic Stress Disorder. Biological Psychiatry, 73(11), 1059–1063. http://doi.org/10.1016/j.biopsych.2012.10.033en_US
dc.identifier.issn0006-3223
dc.identifier.urihttp://hdl.handle.net/11721/1612
dc.description.abstractBACKGROUND: The most effective treatment for posttraumatic stress disorder (PTSD) is exposure therapy, which aims to facilitate extinction of conditioned fear. Recent evidence suggests that brain-derived neurotrophic factor (BDNF) facilitates extinction learning. This study assessed whether the Met-66 allele of BDNF, which results in lower activity-dependent secretion, predicts poor response to exposure therapy in PTSD.en_US
dc.description.abstractMETHODS: Fifty-five patients with PTSD underwent an 8-week exposure-based cognitive behavior therapy program and provided mouth swabs or saliva to extract genomic DNA to determine their BDNF Val66Met genotype (30 patients with the Val/Val BDNF allele, 25 patients with the Met-66 allele). We examined whether BDNF genotype predicted reduction in PTSD severity following exposure therapy.en
dc.description.abstractRESULTS: Analyses revealed poorer response to exposure therapy in the PTSD patients with the Met-66 allele of BDNF compared with patients with the Val/Val allele. Pretreatment Clinician Administered PTSD Scale severity and BDNF Val66Met polymorphism predicted response to exposure therapy using hierarchical regression.en
dc.description.abstractCONCLUSIONS: This study provides the first evidence that the BDNF Val66Met genotype predicts response to cognitive behavior therapy in PTSD and is in accord with evidence that BDNF facilitates extinction learning.en
dc.description.sponsorshipGrant support R01 MH081975/MH/NIMH NIH HHS/United Statesen_US
dc.language.isoenen_US
dc.publisherElservieren_US
dc.subjectBDNFen_US
dc.subjectCBTen_US
dc.subjectFear extinctionen_US
dc.subjectfMRIen_US
dc.subjectGeneticsen_US
dc.subjectPosttraumatic stress disorderen_US
dc.subjectTreatment predictoren_US
dc.subject.meshBrain-Derived Neurotrophic Factor/geneticsen
dc.subject.meshImplosive Therapy/methodsen
dc.subject.meshPolymorphism, Genetic/geneticsen
dc.subject.meshStress Disorders, Post-Traumatic/geneticsen
dc.subject.meshStress Disorders, Post-Traumatic/rehabilitationen
dc.titleThe brain-derived neurotrophic factor Val66Met polymorphism predicts response to exposure therapy in posttraumatic stress disorderen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.biopsych.2012.10.033en_US
dc.local.DepartmentDepartment of Psychiatricen_US
dc.local.FacultySchool of Medicineen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record